Eton Pharmaceutcials
ETON
46 hedge funds and large institutions have $48M invested in Eton Pharmaceutcials in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 6 increasing their positions, 17 reducing their positions, and 21 closing their positions.
77% more call options, than puts
Call options by funds: $750K | Put options by funds: $423K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 50 → 46 (-4)
8.08% less ownership
Funds ownership: 35.99% → 27.91% (-8.1%)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
25% less capital invested
Capital invested by funds: $63.6M → $48M (-$15.6M)
65% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 3 |
Millennium Management
New York
|
+$1,000K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$629K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.82M |
| 2 |
AIC
AWM Investment Company
New York
|
-$2.96M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.57M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.35M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.19M |
ETON Hedge Fund Activity: Q2 2021 in Review
46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q2 2021, worth a combined $48M — down 25% from $63.6M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ETON and 17 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 6 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $1.61M. The largest seller was BlackRock, cutting an estimated $5.82M.
- 46 institutional investors held Eton Pharmaceutcials (ETON) as of Q2 2021, down from 50 in Q1 2021.
- Funds reported $48M of Eton Pharmaceutcials stock for Q2 2021, down 25% quarter-over-quarter.
- 17 funds opened new Eton Pharmaceutcials positions in Q2 2021 and 21 closed out, a net change of -4 holders.
- The largest Eton Pharmaceutcials buyer in Q2 2021 was T. Rowe Price Associates, an estimated $1.61M added.
- The largest Eton Pharmaceutcials seller in Q2 2021 was BlackRock, an estimated $5.82M sold.
Based on aggregated 13F filings for Q2 2021.